Supplementary Table III. Adverse events during baricitinib tapering

Description

Types and frequencies of adverse events recorded during stepwise baricitinib tapering. Data are presented as n/N (%). Events are not mutually exclusive; patients with more than 1 recorded event may appear in multiple rows. Most recorded adverse events were mild, and no event led to adverse event–related baricitinib interruption, discontinuation, or change in the tapering plan.

Categories

Licence